AxoGen (NASDAQ:AXGN) Now Covered by Analysts at Raymond James

Raymond James started coverage on shares of AxoGen (NASDAQ:AXGN) in a research report sent to investors on Monday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $13.00 price target on the medical equipment provider’s stock.

A number of other equities research analysts also recently weighed in on AXGN. Canaccord Genuity Group reissued a buy rating and set a $15.00 price target on shares of AxoGen in a research note on Thursday, June 20th. StockNews.com cut shares of AxoGen from a buy rating to a hold rating in a report on Monday, May 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $12.25.

AxoGen Trading Up 6.5 %

AXGN opened at $7.71 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.43 and a quick ratio of 2.23. The company has a market cap of $337.00 million, a price-to-earnings ratio of -15.42 and a beta of 1.11. The firm has a 50 day simple moving average of $6.67 and a 200 day simple moving average of $7.81. AxoGen has a fifty-two week low of $3.45 and a fifty-two week high of $10.83.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. The business had revenue of $41.38 million during the quarter, compared to the consensus estimate of $42.05 million. AxoGen had a negative net margin of 12.99% and a negative return on equity of 22.18%. On average, sell-side analysts anticipate that AxoGen will post -0.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Silvercrest Asset Management Group LLC boosted its holdings in shares of AxoGen by 4.5% in the first quarter. Silvercrest Asset Management Group LLC now owns 790,647 shares of the medical equipment provider’s stock valued at $6,381,000 after buying an additional 34,399 shares during the period. First Light Asset Management LLC boosted its holdings in shares of AxoGen by 177.0% in the first quarter. First Light Asset Management LLC now owns 765,886 shares of the medical equipment provider’s stock valued at $6,181,000 after buying an additional 489,397 shares during the period. Kent Lake Capital LLC acquired a new position in shares of AxoGen in the first quarter valued at approximately $1,617,000. Panagora Asset Management Inc. boosted its holdings in shares of AxoGen by 69.8% in the fourth quarter. Panagora Asset Management Inc. now owns 165,461 shares of the medical equipment provider’s stock valued at $1,130,000 after buying an additional 68,001 shares during the period. Finally, Rice Hall James & Associates LLC acquired a new position in shares of AxoGen in the first quarter valued at approximately $1,236,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.